NACE 70.10 in FR. Official registry identity, company-size evidence and a rounded indicative valuation range on one indexed company profile.
RELIPHARMA is shown here as a public net-asset reference from filed balance sheets. It is not an earnings-multiple valuation; owner or advisor data is needed for debt, asset quality, leases and marketability adjustments.
Based on official company-size informationCreate a free account to see the detailed curve, the factors that influence it, and an indicative five-year outlook.
Free account · private workspace
This is a public asset-reference range, not an earnings-multiple valuation or a final transaction value. More accuracy requires owner or advisor context.
This company is not currently listed for sale on Upswitch.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
RELIPHARMA is a business in NACE sector 70.10 based in France. The company was founded in 2026, incorporated as a 5710.
RELIPHARMA is listed in French National Business Register (RNE/INPI) under registry number 102355518.
Within the French NACE 70.10 cluster, public-record data is filed annually via the national company registry.
RELIPHARMA's public range combines official company-size information with sector multiples. It remains indicative and is not a midpoint, sale price, offer, or recommendation.
If you are researching RELIPHARMA, this page combines its official registry profile and company-size evidence with a broad indicative range.
RELIPHARMA was founded in 2026 and is registered with French National Business Register (RNE/INPI), incorporated as a 5710.
RELIPHARMA is registered under NACE 70.10: NACE 70.10. That places the business within the French cluster for this activity.
This page shows a rounded, automated indicative range generated by Upswitch from official registry facts, public company-size information, filed accounts where available, and governed sector benchmarks. The evidence basis is labelled beside the graph. It is not a certified or statutory valuation, sale price, offer, recommendation, or financial, investment, tax or legal advice. Figures for RELIPHARMA may be incomplete or inaccurate and must not be relied upon for any transaction; a precise valuation needs owner- or advisor-supplied data.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
